HPV is human papillomavirus. bivalent cervical cancer vaccine is useful at the age of 40 to prevent infection with HPV types 16 and 18.
HPV has been linked to the development of a variety of diseases, with high-risk HPV types 16 and 18 being most closely associated with the development of cervical cancer. In addition, HPV types 16 and 18 can cause vulvar cancer, vaginal cancer, oropharyngeal cancer, perihepatic cancer, genital warts and other diseases.
The bivalent cervical cancer vaccine is available for ages 9-45. After receiving the bivalent cervical cancer vaccine, the vaccine is effective in preventing the infection of two high-risk types of HPV, types 16 and 18.
After the age of 40, the immunity of a woman’s body decreases and her anti-virus ability weakens, making her more susceptible to HPV infection and increasing the chance of cervical cancer. Therefore, it is necessary for women in their 40s to receive the bivalent cervical cancer vaccine.
Cervical cancer screening should be completed before HPV vaccination, and those who meet the requirements for vaccination should follow the doctor’s instructions for vaccination. However, the vaccination does not necessarily mean that you will not get cervical cancer, and you still need to have regular medical checkups.